Impact of oliceridine versus sufentanil on postoperative nausea and vomiting in patients undergoing thyroid surgery: a prospective, double-blind, randomized controlled trial.

Ann MedJun 24, 2026 (epub)
Clinical ResearchAnesthesiologyGeneral SurgeryEndocrinologyOpen access

Feng Liu, Wang Shen, Dan Su et al.

✦ AI-curated · Sources linked

In 30 seconds

This prospective, double-blind, randomized controlled trial evaluated the effects of oliceridine versus sufentanil on postoperative nausea and vomiting (PONV) in 232 patients undergoing thyroid surgery. The study found that the incidence of PONV within 48 hours postoperatively was significantly lower in the oliceridine group (12%) compared to the sufentanil group (28%) with an odds ratio of 0.35.

Key findings

  • Oliceridine group had a PONV incidence of 12% compared to 28% in the sufentanil group (OR = 0.35, p = 0.006).
  • Fewer patients in the oliceridine group required rescue anti-emetics (8% vs 23%, OR = 0.27, p = 0.002).
  • Abdominal distension occurred in 4% of the oliceridine group versus 17% in the sufentanil group (OR = 0.19, p = 0.001).

Why it matters

Postoperative nausea and vomiting can significantly impact recovery and patient satisfaction. This study suggests that oliceridine may be a preferable analgesic option for reducing PONV in patients undergoing thyroid surgery, potentially improving postoperative outcomes.

Source

PubMed · PMID 42339818Free full text on PubMed Central

Published in Ann Med. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Anesthesiology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.